Mitsubishi Tanabe Signs a License Agreement with Viela Bio for its Inebilizumab
Shots:
- Veila Bio to receive $30M upfront licensing fee- additional payment on development and commercial milestones plus royalties on sales of product post-launch
- MTPC to get exclusive rights to develop and commercialize the product in Japan- South Korea- Taiwan- Singapore- Indonesia- Thailand- Malaysia- the Philippines and Vietnam
- Inebilizumab is an anti-CD19 mAb that binds to CD19 with high affinity and is currently under investigation for the treatment of neuromyelitis optica spectrum- disorder (NMOSD)
Click here to read full press release/ article | Ref: Mitsubishi Tanabe | Image: Twitter
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
